You are here: Industry Insights > Natera

News List

Natera, Genentech Initiate Phase III Trial Using Signatera americanpharmaceuticalreview
March 17, 2021
Natera announced the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease (MRD) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial ...
Natera and BGI Genomics announce $50M partnership biospectrumasia
March 12, 2019
Natera, Inc. , a leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., the largest cell-free DNA clinical testing laboratory in China have announced a $50 million partnership to commercialize Natera's Signatera™ MRD test in China, and to d
Natera and Neon Therapeutics Announce Clinical Trial Collaboration pharmafocusasia
November 28, 2018
Natera, Inc., a global leader in cell-free DNA testing, and Neon Therapeutics, Inc., a clinical-stage immuno-oncology company developing neoantigen-based therapeutics.....
Natera Signs Agreement with Bristol-Myers Squibb americanpharmaceuticalreview
September 18, 2018
Natera announced an agreement with Bristol-Myers Squibb to use Natera's Signatera custom circulating tumor DNA assay in a Phase 2 study in the adjuvant...
Natera, Fox Chase Cancer Center Partner for Oncology contractpharma
August 21, 2018
Natera, Inc. has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company's Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for recurrence monitoring of kidney canc
Natera and Institut Jules Bordet partner on breast cancer research pharmaceutical-technology
June 28, 2018
Genetic testing company Natera has partnered with the Belgian Institut Jules Bordet to advance breast cancer research.
Natera Selected for Circulating Tumor DNA Study in Bladder Cancer americanpharmaceuticacreview
September 25, 2017
The study will evaluate over 400 prospectively obtained plasma samples from patients who underwent treatment for bladder cancer, and whose blood was collected serially through chemotherapy and surgery.